Millions of Medicare enrollees with obesity will be able to fill prescriptions for Wegovy and Zepbound at a flat $50 monthly copay starting July 1, 2026. The new Medicare GLP-1 Bridge demonstration, running through December 31, 2027, represents the federal program’s first structured coverage of weight-management drugs in more than two decades. With manufacturers accepting a net price of $245 per monthly supply and Part D plans carrying no financial risk on these fills, the 18-month window is designed as a real-world test of whether covering these medications saves the government money on downstream health costs.
How the $50 copay works and who qualifies
The Bridge program operates entirely outside the normal Part D benefit structure. That means the $50 copay stays the same regardless of which Part D benefit phase a beneficiary is in, whether initial coverage, the coverage gap, or catastrophic. Plans do not opt in or assume risk; CMS administers the drug access directly alongside existing Part D infrastructure, using participating pharmacies and existing claims systems while carving out financial liability for the plans themselves.
Three products qualify for weight management under the Bridge: Foundayo, Wegovy injection and tablets, and Zepbound KwikPen. CMS recently updated its guidance to add Foundayo and to clarify that only the Zepbound KwikPen formulation is included. Beneficiaries need a prior authorization request and a prescription from their provider before filling a Bridge prescription, and they must meet obesity-related clinical criteria that align with current labeling and professional guidelines.
An important distinction applies to people who use these same drugs for non-obesity conditions. Wegovy also carries an FDA-approved indication for reducing risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. Zepbound is separately approved for moderate to severe obstructive sleep apnea in adults with obesity. Prescriptions written for either of those conditions are not Bridge-eligible; they remain covered through standard Part D, where cost-sharing rules differ and where plans still manage utilization and formulary placement under the usual benefit design.
Because the Bridge is layered on top of existing coverage, beneficiaries can move between Bridge fills and traditional Part D fills depending on the indication written on the prescription. Someone who qualifies for Wegovy under the cardiovascular indication, for example, could receive that prescription through the standard Part D benefit while also using a separate Wegovy prescription under the Bridge for weight management, each with its own utilization review and cost-sharing rules.
CBO cost projections and the savings hypothesis
The reason CMS structured this as a time-limited demonstration rather than permanent coverage traces directly to federal budget math. The Congressional Budget Office has modeled the fiscal impact of authorizing broad Medicare coverage of anti-obesity medications and projected costs running into the tens of billions of dollars. That price tag has blocked legislative action for years, and it explains why the Bridge carries a hard end date of December 31, 2027, along with a fixed manufacturer net price and standardized beneficiary copay.
CMS leaders have described the initiative as a bridge between today’s restrictive coverage and a possible future in which weight-loss drugs are treated like other chronic disease therapies. In the agency’s formal announcement, officials emphasized that the demonstration is intended to generate robust data on prescribing patterns, adherence, weight loss, and subsequent health events among older adults with obesity. The implicit bet is that utilization patterns and health outcomes tracked during the 18-month window will show that covering GLP-1 drugs for obesity reduces hospitalizations, cardiovascular events, and other expensive downstream care enough to offset the drug spending itself.
If that evidence materializes, it would give CMS and Congress an empirical foundation to consider permanent Part D coverage for anti-obesity medications, potentially through new legislation or an expansion of existing benefit categories. Conversely, if the data show high drug spending with limited offsetting savings, policymakers will have support for keeping current restrictions in place. Either way, the Bridge is designed as a controlled experiment: CMS sets the price, isolates plan finances from risk, and closely monitors outcomes in a large, real-world Medicare population.
For beneficiaries, the stakes are immediate and concrete. Older adults with obesity who have previously faced list prices exceeding $1,000 per month for GLP-1 drugs will see a predictable $50 monthly out-of-pocket cost for qualifying prescriptions. For clinicians, the Bridge lowers financial barriers but adds administrative steps, including prior authorization and indication-specific prescribing. And for drug manufacturers, the demonstration offers broad Medicare access at a steep discount, in exchange for the possibility that positive results could unlock a much larger, long-term market under standard Part D rules.
As the July 2026 start date approaches, CMS is directing beneficiaries, plans, and prescribers to its dedicated Bridge information hub for updated eligibility criteria, operational details, and timelines. The program’s success will ultimately be judged not only by how many people enroll, but by whether those enrollees experience better health outcomes at a sustainable cost to Medicare and taxpayers.
